Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Biomarkers to Predict Time to Plasma HIV RNA Rebound
NCT03001128 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to collect information about what happens when people pause, or temporarily stop taking, ART, and to collect blood samples from these people at frequent intervals. We will also study the safety of pausing ART under close observation.
Conditions Studied
Interventions
- DRUG Antiretroviral treatment pause
Study Locations (18)
California
- 601 University of California, Los Angeles CARE Center CRS — Los Angeles
- 701 University of California, San Diego AntiViral Research Center CRS — San Diego
- 801 University of California, San Francisco HIV/AIDS CRS — San Francisco
Illinois
- 2701 Northwestern University CRS — Chicago
- Rush Univ. Med. Ctr. ACTG CRS (2702) — Chicago
Massachusetts
- 101 Massachusetts General Hospital (MGH) CRS — Boston
- 107 Brigham and Women's Hosp. ACTG CRS — Boston
North Carolina
- 3201 Chapel Hill CRS — Chapel Hill
- 3203 Greensboro CRS — Greensboro
Colorado
- University of Colorado Hospital CRS (6101) — Aurora
District of Columbia
- Whitman Walker Health CRS (31791) — Washington D.C.
Missouri
- Washington U CRS (2101) — St Louis
New York
- University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787) — Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2017-02-23 |
| Est. Completion | 2021-01-29 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03001128
The ClinicalTrials.gov registry entry for NCT03001128 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 15 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with HIV-1 Infection appearing as the primary indexed condition, and to 1 intervention — of which Antiretroviral treatment pause is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03001128 reports 18 study locations spanning 13 distinct geographic areas — top geographies include California, Illinois, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03001128 about?
NCT03001128 is a clinical study titled "Biomarkers to Predict Time to Plasma HIV RNA Rebound". The purpose of this study is to collect information about what happens when people pause, or temporarily stop taking, ART, and to collect blood samples from these people at frequent intervals. We will also study the safety of pausing ART under close observation.
What is the current status of trial NCT03001128?
This trial is currently completed. The enrollment target is 61 participants. The study started on 2017-02-23. Estimated completion is 2021-01-29.
What conditions does trial NCT03001128 study?
This clinical trial studies the following conditions: HIV-1 Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03001128?
The interventions under investigation include: Antiretroviral treatment pause (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03001128?
This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 15 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03001128 being conducted?
This trial has 18 study locations across California, Colorado, District of Columbia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.